US04272N1028
US04272N1028
ArriVent BioPharma, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 177.534.000 | 94.308.000 | 88.2% | |
| Operating Income | -177.534.000 | -94.308.000 | 88.2% |
| Pretax Income | -166.308.000 | -80.488.000 | 106.6% |
| Net Income Common Stockholders | -166.308.000 | -80.488.000 | 106.6% |
| -- | -- | -- | |
| -- | -- | -- |